Once-weekly Nplate® can provide ITP control—have confidence in your choice1
Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia
and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.
Once-weekly Nplate® can provide ITP control—have confidence in your choice1
This tool provides calculation assistance only. It is not designed or intended to replace the physician’s clinical judgment in determining the appropriate dose for his or her patient.
†The recommended starting dose for Nplate® is 1 mcg/kg.1
Tips for dosing success
†The recommended starting dose for Nplate® is 1 mcg/kg.1
Dose for ITP control and the potential for treatment-free remission1
Use the lowest dose of Nplate® to achieve and maintain a platelet count ≥ 50 x 109/L as necessary to reduce the risk for bleeding. Administer Nplate® as a once-weekly subcutaneous injection with dose adjustments based upon the platelet count response. Do not exceed maximum weekly dose of 10 mcg/kg.1
Titrate Nplate® according to individual
patient response; adjust the weekly dose of
Nplate® by increments of 1 mcg/kg until the patient achieves a
platelet count of
≥ 50 x 109/L, as necessary, to reduce the risk of bleeding.1
Do not exceed maximum weekly dose of 10 mcg/kg.1
To mitigate against medication errors (both overdose and underdose), ensure that the preparation and administration instructions in the full Prescribing Information are followed.
Discontinuation
Discontinue
Nplate® if the platelet count does not increase to a level sufficient
to avoid
clinically important bleeding after 4 weeks of Nplate® therapy
at the maximum weekly dose of 10 mcg/kg. Obtain CBCs, including platelet counts,
weekly for at least 2
weeks following discontinuation of Nplate®.1
Always reference the complete dosing and administration information in the full Prescribing Information for Nplate®. Download now
‡The recommended starting dose for Nplate® is 1 mcg/kg.1 Please see the Nplate® full Prescribing Information for complete dosing instructions, including guidelines for dose adjustments.
Nplate® administration may increase the risk for development or progression of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation of Nplate®. In a clinical trial, one patient with ITP and hemolytic anemia developed marrow fibrosis with collagen during Nplate® therapy.
Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.
Please see full Prescribing Information and Medication Guide.
References: 1. Nplate® (romiplostim) prescribing information, Amgen. 2. Data on file, Amgen.